DMAA is a straight chain, 7 carbon, aliphitic amine with a structural similarity to amphetamine, methamphetamine, and MDMA. It was first introduced as a nasal decongestant but more recently is used as a neurological stimulant and party pill.
DMAA also shares structural similarity to Propylhexedrine, a stimulant drug and nasodilator which may have fat-burning effects in vivo.
Due to its structural similarities, its mechanism of action may be as an adrenaline mimetic; inducing the same effects as adrenaline and the preceding compounds in vivo. However, direct studies on the pharmacokinetics of DMAA metabolism do not exist.
Although seemingly well tolerated in pre-workout supplemental form, DMAA has been linked to a cerebral haemorrhage in a case study with party pill usage.
No long-term toxicity studies are in existence, although acute LD50 of DMAA has been established at 39mg/kg bodyweight intravenous injection and 185mg/kg bodyweight intraperitoneal injection. Theoretically well below what can be achieved via oral ingestion.
DMAA, touted as being a component of geraniums, has been failed to be detected in geranium oil in one independent lab analysis.
DMAA causes a false positive for amphetamines in drug-tested sports competitions and should not be used by athletes being moderated by a drugs ethics association.